Next 10 |
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...
Stealth BioTherapeutics ( NASDAQ: MITO ) said on Friday Robert Weiskopf, its chief financial officer, is leaving the company effective September 30. Weiskopf joined Stealth in 2019 following the initial public offering. For further details see: Stealth Biotherape...
Stealth BioTherapeutics Announces Departure of Chief Financial Officer PR Newswire BOSTON , Sept. 30, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commer...
Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease Events PR Newswire BOSTON , Sept. 15, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development, and...
Stealth BioTherapeutics ( NASDAQ: MITO ) on Monday said it had agreed to go private by being acquired by Morningside Venture (I) Investments, over a month after the clinical-stage biotech received the investment firm's preliminary proposal. MITO stock jumped 19.9% to $...
Stealth BioTherapeutics Corp Enters Definitive Agreement for Going Private Transaction PR Newswire BOSTON , Aug. 1, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, dev...
This seems to be an interesting going private setup currently offering a 10% upside. Majority shareholder Morningside is acquiring the remaining 33% stake in a nanocap biopharmaceutical company Stealth BioTherapeutics. The buyer has indicated that it wants to complete the transact...
A clinical-stage biotechnology company, Stealth BioTherapeutics ( NASDAQ: MITO ) received a letter from Nasdaq on July 7, 2022 for not meeting with minimum bid price and market value of listed securities requirements. Company requests an appeal, trading of the com...
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...